Information Technology Reference
In-Depth Information
Keech, C.L., Farris, A.D., Beroukas, D., Gordon, T.P., and McCluskey, J. (2001) Cognate T-cell
help is sufficient to trigger anti-nuclear autoantibodies in naive mice. J. Immunol. 166:5826-
5834.
Kersh, G.J., Miley, M.J., Nelson, C.A., Grakoui, A., Horvath, S., Donermeyer, D.L., Kappler, J.,
Allen, P.M., and Fremont, D.H. (2001) Structural and functional consequences of altering a
peptide MHC anchor residue. J. Immunol.166:3345-3354.
Kontsek, P., Liptakova, H., and Kontsekova, E. (1999) Immunogenicity of interferon-alpha 2 in
therapy: Structural and physiological aspects. Acta Virol. 43:63-70.
Koren, E., Zuckerman, L.A., and Mire-Suis, A.R. (2002) Immune responses to therapeutic pro-
teins in humans ─ Clinical significance, assessment and prediction. Curr. Pharm. Biotechnol.
3:349-360.
Meister, G.E., Roberts, C.G.P., Berzofsky, J.A., and De Groot, A.S. (1995) Two novel T cell
epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and
published epitopes from Mycobacterium tuberculosis and HIV protein sequences. Vaccine
13:581-591.
Miller, L.L., Korn, E.L., Stevens, D.S., Janik, J.E., Gause, B.L., Kopp, W.C., Holmlund, J.T.,
Curti, B.D., Sznol, M., Smith, J.W., Urba, W.J., Donegan, S.E., Watson, T.M., and Longo, D.L.
(1999) Abrogation of the hematological and biological activities of the interleukin-
3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutraliz-
ing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin. Blood
93:3250-3258.
Mullbacher, A. (1992) Viral escape from immune recognition: Multiple strategies of adenovi-
ruses. Immunol. Cell Biol. 70(Part 1):59-63.
Nilsson, J.B., Nilsson, T.K., Jansson, J.H., Boman, K., Soderberg, S., and Naslund, U. (2002)
The effect of streptokinase neutralizing antibodies on fibrinolytic activity and reperfusion
following streptokinase treatment in acute myocardial infarction. J. Intern. Med. 252:
405-411.
Nissenson, A.R. (2001) Novel erythropoiesis stimulating protein for managing the anemia of
chronic kidney disease. Am. J. Kidney Dis. 38:1390-1397.
Panina-Bordignon, P., Tan, A., Termijtelen, A., Demotz, S., Corradin, G., and Lanzavecchia, A.
(1989) Universally immunogenic T cell epitopes: Promiscuous binding to human MHC class
II and promiscuous recognition by T cells. Eur. J. Immunol. 19:2237-2242.
Pevear, D.C., Luo, M., and Lipton, H.L. (1988) Three-dimensional model of the capsid proteins
of two biologically different Theiler virus strains: Clustering of amino acid difference identi-
fies possible locations of immunogenic sites on the virion. Proc. Natl. Acad. Sci. USA
85:4496-4500.
Prabhakar, S.S., and Muhlfelder, T. (1997) Antibodies to recombinant human erythropoietin
causing pure red cell aplasia. Clin. Nephrol. 47:331-335.
Reijonen, H., Novak, E.J., Kochik, S., Heninger, A., Liu, A.W., Kwok, W.W., and Nepom, G.T.
(2002) Detection of GAD65-specific T-cells by major histocompatibility complex class II
tetramers in type 1 diabetic patients and at-risk subjects. Diabetes 51:1375-1382.
Rosenberg, A.S. (2003) Immunogenicity of biological therapeutics: A hierarchy of concerns.
Dev. Biol. (Basel) 112:15-21.
Ryff, J.C., and Schellekens, H. (2002) Immunogenicity of rDNA-derived pharmaceuticals.
Trends Pharmacol. Sci. 23:254-256.
Scanlan, M.J., and Jager, D. (2001) Challenges to the development of antigen-specific breast
cancer vaccines. Breast Cancer Res. 3:95-98.
Schafer, J.A., Jesdale, B.M., George, J.A., Kouttab, N.M., and De Groot, A.S. (1998) Prediction
of well conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix. Vaccine
16:1880-1884.
